¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2023³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ(1ÀÏÂ÷) : 2023-04-19

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2023³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ(1ÀÏÂ÷) : 2023-04-19
±³À°ÀÏÀÚ : 2023-04-19
±³À°Àå¼Ò : È£ÅÚ ÀÎÅÍºÒ°í ´ë±¸

±³À°ÁÖÁ¦ : 2023³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ(1ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
´ã´çÀÚ : ´ëÇÑÇǺΰúÇÐȸ
¿¬¶ôó : 02-3473-0284  

À̸ÞÀÏ : kda@derma.or.kr

±³À°Á¾·ù : ÇǺΰú

Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ´ë±¸±¤¿ª½Ã
±³À°½Ã°£ : 19 ½Ã°£ 51ºÐ

¼¼ºÎ¼ö°­·á : 500,000¿ø  

ºñ°í Á¤È¸¿ø 80,000 / ÁØȸ¿ø 40,000 / ºñȸ¿ø 500,000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ AB 09:30~09:42 Á¶Á÷ °Ë»ç, ¸é¿ªÇü±¤°Ë»ç ±èÁ¾ÈÆ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ AB 09:42~09:54 Áø±Õ È«Á¾¼ö(µ¿±¹ÀÇ´ë)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ AB 09:54~10:06 ±¤°Ë»ç ¹éÀ¯»ó(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ AB 10:06~10:18 øÆ÷°Ë»ç ±èÁ¤Àº(¼øõÇâÀÇ´ë)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ AB 10:18~10:30 ´õ¸ð½ºÄÚÇÇ°Ë»ç ½Å±âÇõ(ºÎ»êÀÇ´ë)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ AB 10:30~10:42 ½ºÅ×·ÎÀ̵å À̽ÃÇü(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ AB 10:42~10:54 Ç×»ýÁ¦, Ç×Áø±ÕÁ¦ ¼­Çö¹Î(ÇѾçÀÇ´ë)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ AB 10:54~11:06 ¸é¿ª¾ïÁ¦Á¦ ¿ìÀ¯¸®(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ AB 11:06~11:18 ·¹Æ¼³ëÀÌµå ±èűÕ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ AB 11:18~11:30 Ç×È÷½ºÅ¸¹ÎÁ¦ ±Ç¼øÈ¿(°æÈñÀÇ´ë)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ AB 11:30~12:00 Patient centric approach of secukinumab with new updates ±èÁ¤Àº(ÇѾçÀÇ´ë)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ AB 13:10~13:30 One option of vitiligo treatments: Synthetic melanin pigments l-DOPA ³ª°Ç¿¬(Ä¥°îÇǺΰú)

±âŸ 04-19 ÄÁº¥¼ÇȦ AB 13:30~13:35 Introduction Chair(-)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ AB 13:35~13:55 Surgery of acral melanoma Á¤±â¾ç(¿¬¼¼ÀÇ´ë)

Åä·Ð 04-19 ÄÁº¥¼ÇȦ AB 13:55~14:00 Q&A -(-)

±âŸ 04-19 ÄÁº¥¼ÇȦ AB 14:00~14:05 Introduction Chair(-)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ AB 14:05~14:50 Clinical application through studies using mouse models, including post inflammatory pigmentation (PIH) Tamio Suzuki(Yamagata University, Yamagata, Japan)

Åä·Ð 04-19 ÄÁº¥¼ÇȦ AB 14:50~15:00 Q&A -(-)

±âŸ 04-19 ÄÁº¥¼ÇȦ AB 15:30~15:35 Introduction Chair(-)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ AB 15:35~16:25 ÀÏ»óÀ» ¿©Çàó·³, ÀλýÀº °ü±¤°´ ¸ðµå·Î ¹ÚÀ翵(û³âÀÇ»ç ÆíÁýÁÖ°£)

Åä·Ð 04-19 ÄÁº¥¼ÇȦ AB 16:25~16:30 Q&A -(-)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ AB 16:30~16:45 Small molecule treatment for atopy: An overview ¾ÈÁö¿µ(±¹¸³Áß¾ÓÀÇ·á¿ø)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ AB 16:45~17:00 JAK1 inhibitor (abrocitinib) Àå¿ëÇö(°æºÏÀÇ´ë)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ AB 17:00~17:15 JAK1 inhibitor (upadacitinib) ³ªÁ¤ÀÓ(¼­¿ïÀÇ´ë)

Åä·Ð 04-19 ÄÁº¥¼ÇȦ AB 17:15~17:30 Q&A -(-)

±âŸ 04-19 ÄÁº¥¼ÇȦ C 09:30~09:35 Introduction Chair(-)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ C 09:35~10:20 Annals of Dermatology''s new publishing policies for re-leap to top-tier journal Çã¼±(ÇѸ²ÀÇ´ë ±â»ýÃæÇб³½Ç)

Åä·Ð 04-19 ÄÁº¥¼ÇȦ C 10:20~10:30 Q&A -(-)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ C 10:30~10:47 Diagnosis and treatment of oral ulcers ±èÁ¾ÈÆ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ C 10:47~11:04 Genital diseases causing ulceration ½Å¹Î°æ(°æÈñÀÇ´ë)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ C 11:04~11:21 Differential diagnosis of leg ulcers Á¶¼Ò¿¬(¼­¿ïÀÇ´ë)

Åä·Ð 04-19 ÄÁº¥¼ÇȦ C 11:21~11:30 Q&A -(-)

±³À°½Ã°£ 04-19 Áñ°Å¿îȦ 14:00~14:20 PDT for cancerous lesion ¼Û±âÈÆ(±¹¸³¾Ï¼¾ÅÍ)

±³À°½Ã°£ 04-19 Áñ°Å¿îȦ 14:20~14:40 PDT for acne À̱¤ÁØ(´ë±¸Å¬¸°¾÷ÇǺΰú)

±³À°½Ã°£ 04-19 Áñ°Å¿îȦ 14:40~14:53 PDT: Beyond the classic ¹Ú±Í¿µ(Áß¾ÓÀÇ´ë)

Åä·Ð 04-19 Áñ°Å¿îȦ 14:53~15:00 Q&A -(-)

±âŸ 04-19 ÄÁº¥¼ÇȦ C 14:00~14:05 Overview Chair(-)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ C 14:05~14:20 Lifestyle modification for psoriasis ¹éÀ¯»ó(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ C 14:20~14:35 Role of infection and vaccination in psoriasis ¹æöȯ(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ C 14:35~14:50 Drug-induced psoriasis ¹ÚÀºÁÖ(ÇѸ²ÀÇ´ë)

Åä·Ð 04-19 ÄÁº¥¼ÇȦ C 14:50~15:00 Q&A -(-)

±âŸ 04-19 ÄÁº¥¼ÇȦ C 15:30~15:35 Overview Chair(-)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ C 15:35~15:50 Inside atopic dermatitis: Type2 inflammation underlies skin barrier dysfunction and neuroimmune dysregulation ±èÇý¿ø(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ C 15:50~16:05 Type 2 inflammation in the skin ¾ÈÁö¿µ(±¹¸³Áß¾ÓÀÇ·á¿ø)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ C 16:05~16:20 Type 2 inflammation beyond the skin À̼³Èñ(¼øõÇâÀÇ´ë)

±âŸ 04-19 ÄÁº¥¼ÇȦ C 16:20~16:30 Q&A -(-)

±âŸ 04-19 ÄÁº¥¼ÇȦ C 16:30~16:35 Overview Chair(-)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ C 16:35~16:45 Wait-and-see¡¯ vs. ¡®Re-excision¡¯ in incompletely excised BCC/SCC ¹®Á¦È£(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ C 16:45~17:00 What is ¡®Difficult-to-treat¡¯ & Advanced BCC/SCC New classification ±Ç¼øÈ¿(°æÈñÀÇ´ë)

±³À°½Ã°£ 04-19 ÄÁº¥¼ÇȦ C 17:00~17:20 Nonsurgical therapies - Should all BCC/SCCs be surgically excised? ±è¹Î¼º(Á¶¼±ÀÇ´ë)

Åä·Ð 04-19 ÄÁº¥¼ÇȦ C 17:20~17:30 Q&A -(-)

±âŸ 04-19 Áñ°Å¿îȦ 13:30~13:35 Introduction Chair(-)

±³À°½Ã°£ 04-19 Áñ°Å¿îȦ 13:35~13:55 Premature hair graying Á¶¼ºÁø(¼­¿ïÀÇ´ë)

Åä·Ð 04-19 Áñ°Å¿îȦ 13:55~14:00 Q&A -(-)

±³À°½Ã°£ 04-19 Áñ°Å¿îȦ 15:30~15:50 How to achieve outstanding results in acne treatment Á¶ÀçÀ§(°í¿î¹ÌÇǺΰú)

±³À°½Ã°£ 04-19 Áñ°Å¿îȦ 15:50~16:10 Treatment of pigment disorders using Nd:YAG laser ½Å¿µ¹Î(¹ü¾î·ÎÁ¦ÇǺΰú)

±³À°½Ã°£ 04-19 Áñ°Å¿îȦ 16:10~16:30 Customized facial rejuvenation: Lift and fill À̱Ôä(Ȳ±ÝÇǺΰú)

±³À°½Ã°£ 04-19 Áñ°Å¿îȦ 16:30~16:50 Stem cell therapy: Facial skin rejuvenation ±èÀοë(ÇÁ¶óÀ̺êÇǺΰú)

Åä·Ð 04-19 Áñ°Å¿îȦ 16:50~17:00 Q&A -(-)

±âŸ 04-19 Áñ°Å¿îȦ 17:00~17:04 Introduction Chair(-)

±³À°½Ã°£ 04-19 Áñ°Å¿îȦ 17:04~17:21 Inflammatory disease on trunk and extremity ±èÁöÈñ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 04-19 Áñ°Å¿îȦ 17:21~17:38 Malignant tumors on trunk and extremity ÀÌ¿ìÁø(¿ï»êÀÇ´ë)

±³À°½Ã°£ 04-19 Áñ°Å¿îȦ 17:38~17:55 Benign tumors on trunk and extremity ¹®Á¦È£(¼­¿ïÀÇ´ë)

Åä·Ð 04-19 Áñ°Å¿îȦ 17:55~18:00 Q&A -(-)

±âŸ 04-19 ÇູÇÑȦ 09:30~09:35 Overview Chair(-)

±³À°½Ã°£ 04-19 ÇູÇÑȦ 09:35~09:50 Recent issues regarding to ocular safety »ç°ø¹Î(¿µ³²ÀÇ´ë ¾È°ú)

±³À°½Ã°£ 04-19 ÇູÇÑȦ 09:50~10:05 Practical way to protect airway during laser surgery ¼­Çö¹Î(ÇѾçÀÇ´ë)

±³À°½Ã°£ 04-19 ÇູÇÑȦ 10:05~10:20 Laser safety use guidance ±èÇý¼º(°¡Å縯ÀÇ´ë)

Åä·Ð 04-19 ÇູÇÑȦ 10:20~10:30 Q&A -(-)

±³À°½Ã°£ 04-19 ÇູÇÑȦ 10:30~10:55 Foundational evidence and profiles of abrocitinib in atopic dermatitis ÀüÁöÇö(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04-19 ÇູÇÑȦ 10:55~11:20 Challenges of AD & opportunities for better outcome ¾ÈÁö¿µ(±¹¸³Áß¾ÓÀÇ·á¿ø)

Åä·Ð 04-19 ÇູÇÑȦ 11:20~11:30 Q&A -(-)

±³À°½Ã°£ 04-19 ÇູÇÑȦ 14:00~14:50 Managing scalp and nail psoriasis with guselkumab ±èűÕ(¿¬¼¼ÀÇ´ë)

Åä·Ð 04-19 ÇູÇÑȦ 14:50~15:00 Q&A -(-)

±³À°½Ã°£ 04-19 ÇູÇÑȦ 17:00~17:25 How to pick your psoriatic disease treatment in the era of biologic overload, ¡°simple solution¡± ¹éÀ¯»ó(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04-19 ÇູÇÑȦ 17:25~17:50 Be ¡°obJAKtive¡± in safety & adolescent data of upadacitinib ÀÌ»óÀº(¿¬¼¼ÀÇ´ë)

Åä·Ð 04-19 ÇູÇÑȦ 17:50~18:00 Q&A -(-)

±³À°½Ã°£ 04-19 ÇູÇÑȦ 15:30~15:55 Meta-analysis for clinical research À̼־Ï(¿¬¼¼¿øÁÖÀÇ´ë)

±³À°½Ã°£ 04-19 ÇູÇÑȦ 15:55~16:20 Implementation of artificial intelligence to daily clinical practice Á¶¼öÀÍ(¿ÀÅ´½ºÅ¬¸®´Ð)

±³À°½Ã°£ 04-19 ÇູÇÑȦ 16:20~16:45 What is valuable data for digital healthcare? ±èÇöÁ¤(Ãæ³²ÀÇ´ë)

Åä·Ð 04-19 ÇູÇÑȦ 16:45~17:00 Q&A -(-)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2023³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ(1ÀÏÂ÷) : 2023-04-19""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѳ»°úÇÐȸ ¿ï»êÁöȸ ¿¬¼ö°­Á : 2023-04-19
´ÙÀ½±Û 2023ÆòÅýÃÀÇ»çȸ Ãá°èÇмú´ëȸ : 2023-04-18
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20925 ÀüºÏ Á¦ 53Â÷ ´ëÇѳëÀκ´ÇÐȸ È£³²Áöȸ ÇмúÁý´äȸ : 2024-07-27 0 35 2024-05-28
20924 ¼­¿ï 2024 Á¦27ȸ ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-21 0 34 2024-05-28
20923 °æ±â 2024³â ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¾ö : 2024-07-21 0 30 2024-05-28
20922 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(2ÀÏÂ÷) : 2024-07-20 0 26 2024-05-28
20921 ¼­¿ï Á¦33Â÷ ´ç´¢º´ ¿¬±¸ ÇÏ°è¿öÅ©¼¥ : 2024-07-20 0 30 2024-05-28
20920 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancers 2024 : 2024-07-19 0 43 2024-05-28
20919 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(1ÀÏÂ÷) : 2024-07-19 0 17 2024-05-28
20918 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-07-14 0 24 2024-05-28
20917 °æºÏ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2024-07-14 0 22 2024-05-28
20916 °æ±â ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-13 0 22 2024-05-28
20915 °æ±â 2024³â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Á¦1ȸ ½Å°æ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2024-07-13 0 21 2024-05-28
20914 ºÎ»ê Á¦6ȸ ºÎ»ê¼º¸ðº´¿ø ¼Ò¾Æû¼Ò³â°ú ½ÉÆ÷Áö¾ö : 2024-07-13 0 19 2024-05-28
20913 ¼­¿ï 2024 ´ëÇѽŰ泻ºÐºñ¿¬±¸È¸ ¿¬¼ö°­Á : 2024-07-13 0 22 2024-05-28
20912 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦3Â÷¿¬¼ö±³À° : 2024-07-11 0 25 2024-05-28
20911 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-08 0 27 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷